Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 14/20 | 0.56 |
| ▸ | JAK3 | P52333 | 4/20 | 0.56 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.47 |
| ▸ | PLK1 | P53350 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.45 |
| ▸ | JAK1 | P23458 | 1/20 | 0.45 |
| ▸ | STAT6 | P42226 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30051963 | 1.00 | JAK2 (0.56) | JAK2JAK3PIK3CAPIK3CBPIK3CG | |
| SCHEMBL15108219 | 0.85 | JAK2 (0.61) | JAK2JAK3HDAC1JAK1 | |
| SCHEMBL30053338 | 0.77 | ZAP70 (0.56) | JAK2JAK3HDAC1 | |
| SCHEMBL2877271 | 0.77 | ZAP70 (0.56) | JAK2JAK3HDAC1 | |
| SCHEMBL21836042 | 0.76 | LMNA (0.49) | — | |
| SCHEMBL3957543 | 0.72 | JAK2 (1.00) | JAK2JAK3HDAC1JAK1 | |
| SCHEMBL8050839 | 0.72 | MAPK10 (0.58) | JAK2JAK3HDAC1 | |
| SCHEMBL28983303 | 0.70 | ABL1 (0.71) | PIK3CAPIK3CBPIK3CGPLK1HDAC1 | |
| SCHEMBL12801273 | 0.70 | JAK2 (0.78) | JAK2JAK3HDAC1JAK1 | |
| SCHEMBL4382459 | 0.69 | JAK2 (0.59) | JAK2JAK3HDAC1JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220388967-A1 | Phenyl Amino Pyrimidine Compounds and Uses Thereof | SIERRA ONCOLOGY, INC. (US) | 2022-12-08 | — | — | US | claimed |
| EP-3023422-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | YM BioSciences Australia Pty Ltd (AU) | 2016-05-25 | — | — | EP | claimed |
| US-20140011803-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE LLC | 2014-01-09 | — | — | US | claimed |
| US-20100197671-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE LLC | 2010-08-05 | — | — | US | claimed |
| EP-2152701-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | Cytopia Research Pty Ltd (AU) | 2010-02-17 | — | — | EP | claimed |
| WO-2008109943-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | CYTOPIA RESEARCH PTY LTD (AU) | 2008-09-18 | — | — | WO | claimed |
| US-20210309615-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE LLC | 2021-10-07 | — | — | US | disclosed |
| EP-3023422-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | YM BioSciences Australia Pty Ltd (AU) | 2016-05-25 | — | — | EP | disclosed |
| US-9233934-B2 | Phenyl amino pyrimidine compounds and uses thereof | YM BIOSCIENCES AUSTRALIA PTY LTD (US) | 2016-01-12 | — | — | US | disclosed |
| US-20140005180-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE LLC | 2014-01-02 | — | — | US | disclosed |
| US-8486941-B2 | Phenyl amino pyrimidine compounds and uses thereof | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2013-07-16 | — | — | US | disclosed |
| US-20100197671-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE LLC | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197671-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | JAK2, JAK1, JAK3 | JAK2 1/4885JAK3 3/4885PIK3CA 120/4885 |
| US-20140011803-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | JAK2, JAK1, JAK3 | JAK2 1/4885JAK3 3/4885PIK3CA 120/4885 |
| US-20210309615-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | JAK2, JAK1, JAK3 | JAK2 1/4885JAK3 3/4885PIK3CA 120/4885 |
| US-20220388967-A1 | Phenyl Amino Pyrimidine Compounds and Uses Thereof | JAK2, JAK1, JAK3 | JAK2 1/4885JAK3 3/4885PIK3CA 120/4885 |
| US-20140005180-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | JAK2, JAK1, JAK3 | JAK2 1/4885JAK3 3/4885PIK3CA 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.